Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets 03:10:47 2026-02-02 pm EST			5-day change	1st Jan Change
0.000100 ^USD	-.--%		-.--%	+9,900.00%

Dec. 28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	101K 87.27K 81.82K 74.69K 141K 9.68M 141K 971K 379K 4.89M 380K 372K 16.2M	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	11.33M 9.77M 9.16M 8.36M 15.75M 1.08B 15.8M 109M 42.39M 547M 42.55M 41.62M 1.81B	EV / Sales 2022	-	EV / Sales 2023	11,278,456x
Free-Float	89.34%	Yield 2022 *	-	Yield 2023	-

Dec. 28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
25-10-14	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-08-15	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
25-04-30	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
25-04-29	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
24-11-15	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
24-10-17	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
24-10-15	Top Midday Decliners	MT
24-10-14	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
24-09-27	Top Midday Decliners	MT
24-09-24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
24-09-24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

23-09-21	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
23-09-21	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
23-09-21	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
23-05-16	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
23-03-24	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Stock

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Valuation : Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news : Seelos Therapeutics, Inc.

Analysts' recommendations : Seelos Therapeutics, Inc.

Press Releases : Seelos Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Seelos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Annual profits - Rate of surprise

24-11-22	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
24-10-24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
24-10-24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
24-10-15	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
24-10-15	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

Current year	0		0.01
1 year	0		0.01
3 years	0		4,665.6
5 years	0		10,713.61
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	2018-12-31
Michael Golembiewski DFI	Director of Finance/CFO	54	2021-08-31
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/29/24	Michael Golembiewski	Free	Chief Financial Officer	417	0.0043%
1/12/24	Michael Golembiewski	Free	Chief Financial Officer	24,537	0.2505%
1/12/24	Raj Mehra	Free	Chief Executive Officer	70,383	0.7186%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEELOS THERAPEUTICS, INC.	-.--%	-.--%	+9,900.00%	-100.00%	136
WUXI APPTEC CO., LTD.	-1.59%	-3.35%	+52.37%	+93.70%	69.54B
ARGENX SE	-1.34%	-0.75%	+48.21%	+91.86%	64.97B
WUXI BIOLOGICS (CAYMAN) INC.	+0.30%	-0.69%	+52.56%	+10.23%	26.51B
INSMED INCORPORATED	-2.35%	-5.75%	-12.90%	+448.54%	25.89B
BIONTECH SE	-8.37%	-12.43%	+2.08%	-16.71%	25.64B
PHARMAESSENTIA CORPORATION	-0.96%	+10.36%	+283.06%	+436.50%	20.22B
GENMAB A/S	-0.51%	+0.23%	+35.77%	-18.70%	19.98B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.91%	-4.37%	+13.28%	+535.19%	15.69B
EXELIXIS, INC.	-1.47%	+0.68%	+45.51%	+143.08%	13.49B
Average	-1.82%	-1.73%	+1,041.99%	+162.37%	28.19B
Weighted average by Cap.	-1.93%	-1.50%	+53.73%	+151.51%

	2022	2023
Net sales	-	2.2 1.9 1.78 1.62 3.06 210.55 3.07 21.12 8.24 106.28 8.27 8.09 352.42
Net income	-73.53M -63.36M -59.41M -54.23M -102M -7.03B -102M -705M -275M -3.55B -276M -270M -11.76B	-37.88M -32.64M -30.61M -27.94M -52.63M -3.62B -52.8M -363M -142M -1.83B -142M -139M -6.06B
Net Debt	4.59M 3.95M 3.71M 3.38M 6.38M 439M 6.4M 43.99M 17.16M 221M 17.23M 16.85M 734M	11.23M 9.68M 9.07M 8.28M 15.61M 1.07B 15.66M 108M 42.01M 542M 42.17M 41.25M 1.8B